Patents by Inventor Anja GIESE
Anja GIESE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230065629Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 4, 2021Publication date: March 2, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Anja GIESE, Jürgen KLAR, Alexander Helmut Michael EHRMANN, Jens WILLWACHER, David ENGEL, Andre Philippe DIESKAU, Antje KAHNERT, Alexey GROMOV, Carsten SCHMECK, Niels LINDNER, Thomas MÜLLER, Anna Lena ANDREEVSKI, Jan DREHER, Karl COLLINS
-
Patent number: 11208400Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 9, 2017Date of Patent: December 28, 2021Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Anja Giese, Jürgen Klar, Alexander Helmut Michael Ehrmann, Jens Willwacher, David Engel, Andre Philippe Dieskau, Antje Kahnert, Alexey Gromov, Carsten Schmeck, Niels Lindner, Thomas Müller, Anna Lena Andreevski, Jan Dreher, Karl Collins
-
Publication number: 20200055842Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 9, 2017Publication date: February 20, 2020Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Anja GIESE, Jürgen KLAR, Alexander Helmut Michael EHRMANN, Jens WILLWACHER, David ENGEL, Andre Philippe DIESKAU, Antje KAHNERT, Alexey GROMOV, Carsten SCHMECK, Niels LINDNER, Thomas MÜLLER, Anna Lena ANDREEVSKI, Jan DREHER, Karl COLLINS
-
Patent number: 10487092Abstract: The present invention relates to substituted pyrazolopyridinamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, inflammatory disease and disease associated with inflammatory pain, as a sole agent or in combination with other active ingredients.Type: GrantFiled: December 14, 2015Date of Patent: November 26, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Anja Giese, Ulrich Klar, Keith Graham, Georg Kettschau, Detlev Sülzle, Philip Lienau, Kirstin Petersen, Julien LeFranc, Nicole Schmidt
-
Publication number: 20180162877Abstract: The present invention relates to substituted pyrazolopyridinamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, inflammatory disease and disease associated with inflammatory pain, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 14, 2015Publication date: June 14, 2018Inventors: Anja GIESE, Ulrich KLAR, Keith GRAHAM, Georg KETTSCHAU, Detlev SÜLZLE, Philip LIENAU, Kirstin PETERSEN, Julien LEFRANC, Nicole SCHMIDT
-
Publication number: 20180042931Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) wherein LA represents *CH2** or *?**; wherein indicates the point of attachment to the carbonyl group, and ** indicates the point of attachment to R1; LB represents *N(H)—C(?O)** or *C(?O)—N(H)**; wherein * indicates the point of attachment to R2, and ** indicates the point of attachment to the phenyl group; R1 represents a group selected from: (AA); wherein * indicates the point of attachment to LA, R2 represents: (BB) wherein * indicates the point of attachment to R3, and ** indicates the point of attachment to LB R3 represents a group selected from: (CC); wherein * indicates the point of attachment to R2; R4 and R5 represent a hydrogen atom; and R6 represents a halogen atom or group selected from: —CH3, —O—CH3, —O—CHF2, —O—CF3, and —O-cyclopropyl; to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturingType: ApplicationFiled: February 16, 2016Publication date: February 15, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Kai THEDE, Eckhard BENDER, William J. SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PÜHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES
-
Publication number: 20180044306Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: February 16, 2016Publication date: February 15, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Kai THEDE, Eckhard BENDER, William J. SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PÜHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES, Jens GEISLER
-
Publication number: 20180028507Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients, in which: R1 represents a group selected from: C1-C3-alkoxy-C2-C3-alkyl-, (A), (B), (C), (D), (E), (F), (G) or (H); wherein * indicates the point of attachment to the rest of the molecule; R2 represents a group selected from: (I), (J) or (K); wherein * indicates the point of attachment to the rest of the molecule.Type: ApplicationFiled: February 16, 2016Publication date: February 1, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Kai THEDE, Eckhard BENDER, William J. SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PÜHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES
-
Publication number: 20170197979Abstract: The present invention relates to substituted benzothiadiazolamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 26, 2015Publication date: July 13, 2017Inventors: Anja GIESE, Ulrich KLAR, Georg KETTSCHAU, Detlev SÜLZLE, Philip LIENAU, Kirstin PETERSEN
-
Publication number: 20170114070Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: March 18, 2015Publication date: April 27, 2017Inventors: Kai THEDE, Eckhard BENDER, William SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PUEHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES, Jens GEISLER
-
Publication number: 20170107229Abstract: The present invention relates to substituted tetrahydropyridothienopyrimidine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 22, 2015Publication date: April 20, 2017Inventors: Ulrich KLAR, Anja GIESE, Georg KETTSCHAU, Knut EIS, Detlev SÜLZLE, Philip LIENAU, Kirstin PETERSEN
-
Publication number: 20170107212Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: March 18, 2015Publication date: April 20, 2017Inventors: Kai THEDE, Eckhard BENDER, William SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PUEHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES, Jens GEISLER